| Active Not Recruiting | A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women NCT06592586 | Minervax ApS | Phase 2 / Phase 3 |
| Not Yet Recruiting | Model-informed Precision Dosing for Linezolid NCT06444802 | University of Hamburg-Eppendorf | Phase 3 |
| Recruiting | Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease NCT05824988 | Shanghai Pulmonary Hospital, Shanghai, China | — |
| Withdrawn | Dalbavancin Outpatient Pilot NCT03982030 | Wake Forest University Health Sciences | Phase 4 |
| Completed | Clinical Decision Support Tool for Vancomycin Dosing in Children NCT04911270 | University of Maryland, Baltimore | N/A |
| Unknown | The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogen NCT04917380 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Terminated | Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition NCT04847921 | University of Colorado, Denver | Phase 2 / Phase 3 |
| Completed | Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resist NCT03896685 | Médecins Sans Frontières, France | Phase 3 |
| Completed | TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection NCT03964493 | TenNor Therapeutics Limited | Phase 2 |
| Completed | Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection NCT03747497 | MicuRx | Phase 2 |
| Completed | Controlled Human Infection for Vaccination Against Streptococcus Pyogenes NCT03361163 | Andrew Steer | Phase 1 |
| Unknown | Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill P NCT03438214 | University of Sao Paulo | Phase 4 |
| Completed | A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants NCT03159403 | Melinta Therapeutics, Inc. | — |
| Completed | A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, Wi NCT02750761 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | Telavancin Pediatric PK Study (Ages >12 Months to 17 Years) NCT02013141 | Cumberland Pharmaceuticals | Phase 1 |
| Completed | Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients NCT03560440 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Particip NCT02134301 | Melinta Therapeutics, LLC | Phase 1 |
| Completed | Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative P NCT01412801 | Novartis Vaccines | Phase 2 |
| Unknown | Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a NCT01212432 | University of Zurich | Phase 2 |
| Terminated | Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflam NCT00835783 | Odense University Hospital | — |
| Completed | What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Prese NCT00736554 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | — |
| Terminated | A Study of Ceftobiprole in Patients With Fever and Neutropenia. NCT00529282 | Basilea Pharmaceutica | Phase 3 |
| Completed | Early-Onset Sepsis Surveillance Study NCT00874367 | NICHD Neonatal Research Network | — |
| Terminated | Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections NCT00108433 | Pfizer | Phase 3 |
| Completed | Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Inf NCT00501150 | Imperial College London | N/A |
| Completed | Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receivin NCT00136292 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Completed | Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units NCT00167999 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit NCT00167960 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Post Marketing Surveillance Study on Linezolid NCT01564758 | Pfizer | — |
| Completed | Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) NCT00079976 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia NCT00062647 | Cumberland Pharmaceuticals | Phase 2 |
| Completed | Time To Efficacy and Onset Of Action Of Linezolid NCT00147511 | Pfizer | Phase 4 |
| Terminated | Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria NCT00055198 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Completed | Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized S NCT00081744 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria NCT00037050 | Pfizer | Phase 3 |
| Completed | New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae P NCT00035269 | Pfizer | Phase 3 |
| Terminated | Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric NCT00240747 | Pfizer | Phase 3 |
| Completed | Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis NCT00406198 | Hopital Lariboisière | Phase 4 |